Subtype
Malignant Large Intestinal Neoplasm
CI-CAN-00003173Explore in graph →
1,622 active trials21 approved drugs383 evidence items
- NCIt
- C215202
Loading cancer entity…
Subtype
CI-CAN-00003173Explore in graph →
Clinical trials
7,502 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (742)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06520683 | Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer(SMALLER) | recruiting | Phase 3 | 180 | Sun Yat-sen UniversityOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT06652529 | Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors(AROG4-01-01) | not yet recruiting | Phase 1 | 35 | Aromics TherapeuticsINDUSTRY | 0 | Nov 7, 2024 |
| clinicaltrials |
| NCT06530303 | Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer(BAH248) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT04103372 | Pre-therapeutic MRI Assessment of Early-Stage Rectal Cancer and Significant Rectal Polyps to Avoid Major Resectional Surgery(PRESERVE) | recruiting | N/A | 200 | Imperial College LondonOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT04296630 | Social Media for Colorectal Cancer Screening | enrolling by invitation | N/A | 56,000 | Unity Health TorontoOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT05424692 | Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer | recruiting | N/A | 200 | Peking Union Medical College HospitalOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT05674422 | GEMCAD-REVEAL STUDY - Circulating Tumor DNA as a Predictor of Relapse in Patients With Locally Advanced Rectal Cancer.(REVEAL) | active not recruiting | — | 120 | Grupo Espanol Multidisciplinario del Cancer DigestivoOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT06665334 | To Explore the Effect of Huaier Granule on the Negative Conversion Rate After the CEA Level Increases Again After Colorectal Cancer Surgery | not yet recruiting | Phase 4 | 134 | Fudan UniversityOTHER | 0 | Oct 31, 2024 | clinicaltrials |
| NCT06665087 | CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC | not yet recruiting | Phase 2 | 110 | Fudan UniversityOTHER | 0 | Oct 30, 2024 | clinicaltrials |
| NCT06666166 | SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer | not yet recruiting | Phase 2 | 28 | Yunpeng LiuOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT06662643 | A Clinical Trial Comparing Staged Turnbull-Cutait Pull-through Anastomosis With Direct Anastomosis Plus Prophylactic Ileostomy in the Treatment of Low Rectal Cancer After Internal Sphincter Resection(STAR-TAR) | active not recruiting | N/A | 110 | Zhongnan HospitalOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT04161092 | The Swedish Study of Liver Transplantation for Non-resectable Colorectal Cancer Metastases(SOULMATE) | active not recruiting | N/A | 45 | Vastra Gotaland RegionOTHER_GOV | 1 | Oct 28, 2024 | clinicaltrials |
| NCT06652412 | CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC | not yet recruiting | Phase 2 | 124 | Fudan UniversityOTHER | 0 | Oct 28, 2024 | clinicaltrials |
| NCT04516681 | Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer | recruiting | Phase 3 | 400 | Fudan UniversityOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT06653452 | Application of PET/MRI in the Evaluation of the Efficacy of Neoadjuvant Therapy for Locally Advanced Rectal Cancer | recruiting | N/A | 30 | Peking Union Medical College HospitalOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT06653478 | Development and Demonstration of Intelligent Assessment Based on Multi-modal Information Fusion for Tumor Risk and Diagnosis and Treatment | recruiting | — | 3,000 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT03635021 | Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer(CR-SEQUENCE) | active not recruiting | Phase 3 | 419 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT06207656 | Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer(CEBBRA) | recruiting | Phase 2 | 70 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT02579278 | Circulating Tumour DNA (ctDNA) in Patients With Colorectal Cancer and the Relationship to Imaging Features of Extramural Venous Invasion(ctDNA) | recruiting | — | 100 | Imperial College LondonOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT02704520 | Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker - Phase III Non CTIMP Trial(TRIGGER) | recruiting | N/A | 441 | Imperial College LondonOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT03303547 | Concordance of Imaging and Pathology Diagnosis of Extranodal Tumour Deposits(COMET) | recruiting | N/A | 200 | Imperial College LondonOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT04547166 | A Clinical Study to Evaluate Efficacy and Safety of Serplulimab(HLX10) Combined With Bevacizumab(HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC) | recruiting | Phase 2 / Phase 3 | 568 | Shanghai Henlius BiotechINDUSTRY | 2 | Oct 17, 2024 | clinicaltrials |
| NCT06275958 | DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer(DOSAGE) | recruiting | Phase 3 | 587 | Leiden University Medical CenterOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06633133 | Virtual Ileostomy Versus Diverting Ileostomy in Patients Undergoing Total Mesorectal Excision | recruiting | N/A | 620 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06643429 | Impact of Environmental Factors and Metabolomics on Colorectal Cancer. | active not recruiting | — | 700 | Dong PengOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06645301 | BGT007 Treatment for Recurrent/refractory Gastrointestinal Malignancies | not yet recruiting | Early Phase 1 | 15 | BioSyngen Pte LtdINDUSTRY | 0 | Oct 16, 2024 | clinicaltrials |
| NCT04584008 | Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics(VISIONARY) | active not recruiting | N/A | 600 | Peking UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT05250648 | Clinical Trial on HIPEC With Mitomycin C in Colon Cancer Peritoneal Metastases (GECOP-MMC)(GECOP-MMC) | recruiting | Phase 4 | 216 | Hospital Universitario de FuenlabradaOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT05955196 | Test of CD47-SIRPα Inhibitors on the Immune Microenvironment Colon Cancer(MACROSWITCH) | recruiting | — | 115 | Institut Paoli-CalmettesOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06184698 | Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer | recruiting | Phase 2 | 173 | Hebei Medical University Fourth HospitalOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06632886 | AI-Assisted Non-Contrast CT for Multi-Cancer Screening | recruiting | N/A | 1,000,000 | Guo ShiWeiOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06220045 | Comparing PP and PVDF Meshes in Midline Laparotomy Closure for High-risk Colorectal Surgery. Impact on Incisional Hernia and Surgical Wound Infection.(PROFIMESH) | recruiting | N/A | 60 | Institut d'Investigació Biomèdica de Girona Dr. Josep TruetaOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT06220058 | Comparing Polypropylene Mesh and "Small Bites" Technique in Emergency Colorectal Surgery's Midline Laparotomy Closure. Study for Incisional Hernia Prevention.(BITEME) | recruiting | N/A | 148 | Fernandez ZamoraOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT06452745 | Early Diagnosis of Colorectal Cancer Based on a Non-invasive Metabolomics Profile(EarlyCRC) | recruiting | — | 2,000 | Institut Investigacio Sanitaria Pere VirgiliOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT05628038 | The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer(TORCH-R) | recruiting | Phase 2 | 93 | Fudan UniversityOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06619743 | HPV Infection and Vaginal Microecology in Immunosuppressed Women | not yet recruiting | — | 10,000 | Lan ZhuOTHER | 0 | Oct 1, 2024 | clinicaltrials |
| NCT06619886 | TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor | not yet recruiting | Early Phase 1 | 9 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT04117945 | Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer | active not recruiting | Phase 2 | 22 | Academic and Community Cancer Research UnitedOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06614660 | Metabolism Imaging-genomics for Predicting the Surgical Outcomes of Colorectal Cancer | active not recruiting | — | 800 | First Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06614699 | Predictive Effect of Abdominal Fat and Muscle Area Calculated Based on Abdominal CT on Colorectal Cancer Patients | active not recruiting | — | 8,000 | First Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06614751 | A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway | not yet recruiting | Phase 1 | 112 | Danatlas Pharmaceuticals Co., LtdINDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06616259 | First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study(CAPCET-III) | not yet recruiting | Phase 3 | 452 | Meng QiuOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06616870 | Study of the Predictive and Prognostic Role of Pharmacogenetic and Radiogenic Variants on the Response to Neoadjuvant Chemoradiation Therapy in Patients With Locally Advanced Rectal Cancer(IGLarc) | not yet recruiting | — | 460 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06613399 | Multi-Technology Integrated Total Mesorectal Excision Versus Conventional Total Mesorectal Excision for the Treatment of Middle and Distal Rectal Cancer. | not yet recruiting | N/A | 324 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Sep 26, 2024 | clinicaltrials |
| NCT06613581 | Patient-led Follow-up from Home After Surgery for Colorectal Carcinoma(PROMISE) | recruiting | N/A | 200 | Erasmus Medical CenterOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT05656326 | Follow-up After Surgery for Colorectal Cancer(FUTURE-primary) | active not recruiting | — | 200 | Erasmus Medical CenterOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT06259552 | A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors(SPX-303) | recruiting | Phase 1 | 232 | SparX Biotech(Jiangsu) Co., Ltd.OTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT06609551 | ctDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer Patients After Surgery: A Single-center, Randomized, Controlled Study(ZJCH-CRCC-1) | recruiting | Phase 3 | 312 | Zhejiang Cancer HospitalOTHER | 1 | Sep 24, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 7, 2024source: clinicaltrials